Joshua Schafer Sells 10,500 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock

by · The Cerbat Gem

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) insider Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $9.19, for a total value of $96,495.00. Following the transaction, the insider owned 62,278 shares of the company’s stock, valued at $572,334.82. This represents a 14.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Joshua Schafer also recently made the following trade(s):

  • On Friday, January 30th, Joshua Schafer sold 3,375 shares of Zevra Therapeutics stock. The shares were sold at an average price of $8.83, for a total value of $29,801.25.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock traded down $0.22 during mid-day trading on Wednesday, hitting $8.94. 882,575 shares of the company were exchanged, compared to its average volume of 1,029,253. Zevra Therapeutics, Inc. has a 12-month low of $6.19 and a 12-month high of $13.16. The company has a market capitalization of $503.32 million, a P/E ratio of 19.02 and a beta of 0.99. The business’s 50 day simple moving average is $8.67 and its two-hundred day simple moving average is $9.41. The company has a debt-to-equity ratio of 0.46, a current ratio of 8.62 and a quick ratio of 8.57.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The business had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. Analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Trading of Zevra Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ZVRA. CWM LLC raised its holdings in shares of Zevra Therapeutics by 399.5% in the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after purchasing an additional 2,297 shares during the period. Ameritas Investment Partners Inc. increased its position in Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after purchasing an additional 1,280 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares during the period. Tower Research Capital LLC TRC raised its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares during the period. Finally, Creative Planning acquired a new position in Zevra Therapeutics during the second quarter valued at approximately $92,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on ZVRA. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Cantor Fitzgerald lowered their target price on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Finally, HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research report on Tuesday, December 30th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.80.

Read Our Latest Stock Report on ZVRA

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

Further Reading